3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Withdrawn
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
1
Sarcoma
1
Gastrointestinal
1
Breast
1
Conditions
Solid Tumors
2
Neoplasms
2
Liposarcoma
2
Biliary Tract Neoplasms
2
Urinary Bladder Neoplasms
1
Triple Negative Breast Neoplasms
1
Tertiary Lymphoid Structures
1
Solid Tumours
1
Sarcoma
1
Pancreatic Neoplasms
1
Lung Neoplasms
1
Histiocytoma, Malignant Fibrous
1
Glioblastoma
1
Dermatofibrosarcoma
1
Colorectal Neoplasms
1
Carcinoma, Non-Small-Cell Lung
1
Interventions
tazemetostat
1
relatlimab
1
regorafenib
1
durvalumab
1
brigimadlin
1
bintrafusp alfa protein, human
1
Nivolumab
1
Doxorubicin
1
Clinical Trials, Phase II as Topic
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Interventional
×
Tertiary Lymphoid Structures
×
brigimadlin
×
Clear all
NCT06084689
2025-09-02
EMPIRE
Institut Bergonié
Phase 2
Withdrawn